maintenance on tirzepatide for of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial Tirzepatide Drops — Maintenance Plan
Description
Your Doctors, Your Care Kaiser Permanente of Northern California
Based on this review, evidence from head-to-head and insulin-comparator trials demonstrates that dual GIP/GLP-1 co-agonism consistently overcomes metabolic plateaus that result from single-pathway therapy, producing superior glycated hemoglobin reduction, bariatric-level weight loss (up to 25.3%), and robust macrovascular and heart failure protection, including a 38% reduction in composite cardiovascular risk among patients with heart failure with preserved ejection fraction (HFpEF)
After three months, all 10 patients of the study were able to stop taking prandial insulin.
Expert guidance on safety, timing, and monitoring requirements.
Read an editorial review of AgelessRx: GLP-1 medication options, pricing tiers, compounded-pharmacy pathway, and program structure
B12 and semaglutide can be used together, but individual nutritional status and genetic factors influence efficacy and tolerability
